Patients living with HIV (human immunodeficiency virus) must take antiretroviral therapy (ART) for their entire lives — which often leads to side effects — because there is no cure at this time. Recently, there have been reports of toxicity in patients taking tenofovir, an antiviral medicine that is used to treat HIV.
A new study by Elijah Paintsil, MD, Karen Anderson, PhD, and other Yale colleagues, along with researchers at CSIC in Madrid Spain (Luis Blanco and his colleague), examines the catalytic activity of PrimPol and effects of tenofovir in the lab, as well as a personalized medicine approach, of HIV+ patients on tenofovir-based Anti-Retroviral Therapy (ART) with mitochondrial toxicity.
Read the full study, “Identifying the role of PrimPol in TDF-induced toxicity and implications of its loss of function mutation in an HIV+ patient“ on Nature.com to learn more.
Vincent Duong, Lei Zhou, Linh He, and Moises Cosme from Yale and María Martínez-Jiménez from CSIC also collaborated on this study.